PHAT News and Press, Phathom Pharmaceuticals Inc. From 08/02/22

Phathom Pharmaceuticals press release ( NASDAQ: PHAT ): Q2 GAAP EPS of -$1.33 misses by $0.30 . Net loss for the Q2 2022 was $50.9M. For further details see: Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30

Erosive Esophagitis (EE) New Drug Application (NDA) accepted by U.S. Food and Drug Administration (FDA) with Prescription Drug User Fee Act (PDUFA) action date of January 11, 2023; if approved, targeting U.S. launch in Q1 2023 VOQUEZNA DUAL and TRIPLE PAK approved by FDA for treat...

Today, we put Phathom Pharmaceuticals in the spotlight for the first time. The company just got one FDA approval and is in the process of garnering another for its primary drug candidate vonoprazan. The drug is licensed from Takeda and has seen impressive sales in Japan. An i...

FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will pa...

The U.S. Food and Drug Administration (FDA) accepted to review Phathom Pharmaceuticals' (NASDAQ:PHAT) application seeking approval of oral medicine vonoprazan to treat adults with erosive esophagitis (EE). The company's New Drug Application (NDA) for vonoprazan is for ...

FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted f...

Results from an investigational Phase 3 PHALCON-EE trial demonstrating superior healing at week 2 in patients with LA Grade C/D (moderate-to-severe) erosive esophagitis and superior maintenance of healing at week 24 in all patients with vonoprazan versus lansoprazole shared in oral presen...

Shares of Phathom Pharmaceuticals (NASDAQ:PHAT) are trading higher for the third straight session on Tuesday after three top executives of the clinical-stage biopharma company made a series of insider purchases in recent days.   Phathom’s (PHAT) Chief Executive Curran Terrie,...

Gainers: Scholar Rock (SRRK) +26%. Phathom Pharmaceuticals (PHAT) +12%. 4d Pharma  (LBPS) +10%. Ocular Therapeutix (OCUL) +9%. Magenta Therapeutics (MGTA) +8%. Losers: PolarityTE (PTE) -34%. Tonix Pharmaceuticals (TNXP) -22%. Albireo Pharma (ALBO) ...

New investigational data evaluating vonoprazan in erosive esophagitis (EE) Research highlights real-world evidence of unmet needs that exists for the treatment of Helicobacter pylori ( H. pylori ) infection Phathom research recognized with multiple “posters ...